Skip to main content
Caplight Logo









Nuritas

Nuritas

Private
DublinHealthcare & Life Scienceshttps://nuritas.com

Last Round

Series C

Dec 20, 2024

Total Funding Raised

$146.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Nuritas operates in Healthcare & Life Sciences and is based in Dublin. Its latest recorded funding round was a Series C round in December 2024.

Nuritas is a biotechnology company that utilizes a platform combining artificial intelligence and genomics to discover and unlock natural bioactive peptides for use in dietary supplements, functional foods, and cosmetics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Nuritas Comparables

Compare Nuritas with similar companies based on industry and business-model similarity.

Nuritas comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shiru
87%
Brightseed
83%
Protera
81%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Nuritas Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CDec 20, 2024
Series BNov 11, 2021
DebtNov 29, 2018
Series ADec 20, 2017
SeedDec 7, 2016
Seed
Oct 26, 2015
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Nora K.

Founder, CEO

Founding Team

Alison Anderson MBA CIPD

Chief People Officer

Executive Team

John Casey

Chief Manufacturing and Supply Chain Officer

Executive Team

For institutional investors. Book with your work email.

Nuritas Investors

Notable investors and investment history

Nuritas investors
InvestorRounds
Cultivian Sandbox VenturesSeries B, Series A
Grosvenor Food & AgTechSeries C, Series B
McWin Capital PartnersSeries C
European Investment Bank GroupDebt
M&G InvestmentsSeries C
Cleveland AvenueSeries B
Clay CapitalSeries A, Seed, Series B
Book a demo to see all 11 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 36% MoM, from 12.4K to 16.9K.

  • May 5, 2026

    Exhibiting at Vitafoods Europe 2026 in Barcelona.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • partners_withNov 11, 2026

    On Nov 10th '26 in Ireland, Nuritas announces a partnership with University of Limerick under which it becomes a founding industry residency partner in the Immersive Bioscience and Biotherapeutics (iBio) programme.

  • hiresSep 10, 2026

    On Sep 10th '26 in Ireland, Nuritas appoints former Unilever North America President Kees Kruythoff as Chair of its Board of Directors to bring global scaling and commercialization expertise to the biotech company.

Book a demo to see all news

For institutional investors. Book with your work email.

Nuritas Filings

Explore SEC and related filing metadata, where available.

Nuritas filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Nuritas's valuation, stock price, and market status.

Is Nuritas a public or private company?

Nuritas is a private company.

What is the current stock price of Nuritas?

Nuritas is a private company, so its shares have no public market price. Caplight tracks Nuritas's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Nuritas worth (valuation)?

Valuation information for Nuritas is not publicly available.

Can I buy Nuritas stock?

Nuritas shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Nuritas's last funding round?

Nuritas's most recent funding round was Series C on December 20, 2024.

Who are the main investors in Nuritas?

Key investors in Nuritas include Cultivian Sandbox Ventures, M&G Investments, Cleveland Avenue, Clay Capital.

Will Nuritas IPO soon?

No public IPO plans have been announced for Nuritas.

How can I track Nuritas secondary market activity?

Caplight tracks bids, offers, and trades in Nuritas's shares on secondary markets.

Firmographic Details

HeadquartersDublin
Employee Range66
Year Founded2014
Last FundingDec 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?